Morgan Stanley has upgraded Vir Biotechnology ( VIR, Financial) and uplifted its price target for the stock to $20 from ...

Global brokerage Goldman Sachs on Thursday lowered its target price for Reliance Industries Ltd (RIL), while maintaining 'buy' rating for the diversified group. The brokerage reduced RIL's target ...

Experian's (LON:EXPN) outlook for margin expansion is "robust" and underpins the potential for sustained organic growth, according to analysts at Morgan Stanley (NYSE:MS).

Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...

HSBC predicts a 21% rise in Hong Kong-listed Chinese stocks by 2025, driven by favourable policy shifts in mainland China.

Equity valuations are undeniably elevated, with the S&P 500 currently trading at approximately 22.5x forward earnings.

One of the key attribution to the selling pressure in Tata Motors is due to softer sales data with brokerages trimming their ...

US investment banks have little room for error in their upcoming full-year results. With share prices of almost all the major ...

The growth was fuelled by equity capital markets growing to US$108.7 million, a 42% increase, matched by a similar surge in ...

The realty sector emerged as the top laggard, shedding over 1.5 per cent, followed by declines in banking, auto, and energy ...

Morgan Stanleys Chief US Equity Strategist, Mike Wilson, forecasts a volatile first half of 2025, with recovery prospects ...